---
title: "Xeris Pharmaceuticals Q2 2026 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294997328.md"
description: "Xeris Pharmaceuticals (XERS) will report Q2 2026 earnings on August 5th after market close. Consensus estimates project EPS of $0.00 and revenue of $90.13M, representing a 26.1% year-over-year increase. Over the past three months, analysts have revised EPS estimates upward once with no downward revisions, while revenue estimates have seen two upward and four downward adjustments."
datetime: "2026-08-05T17:33:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294997328.md)
  - [en](https://longbridge.com/en/news/294997328.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294997328.md)
generator: "portal-rs"
---

# Xeris Pharmaceuticals Q2 2026 earnings preview

Xeris Pharmaceuticals (XERS) is scheduled to announce Q2 earnings results on Wednesday, August 5th, after market close. The consensus EPS Estimate is $0.00 and the consensus Revenue Estimate is $90.13M (+26.1% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue estimates have seen 2 upward revisions and 4...

### Related Stocks

- [XERS.US](https://longbridge.com/en/quote/XERS.US.md)

## Related News & Research

- [medmix' Drug Delivery ("Haselmeier") to Support the Development of Xeris Pharmaceuticals' XP-8121 with D-Flex(TM) Pen Injector | MDMXF Stock News](https://longbridge.com/en/news/298551232.md)
- [XERS: XP-8121 targets a $1-3B market with a 2030 launch, leveraging clinical innovation and strong physician demand](https://longbridge.com/en/news/298461309.md)
- [InMed Pharmaceuticals GAAP EPS of -$3.12](https://longbridge.com/en/news/298502732.md)
- [Concurrent Investment Advisors LLC Acquires 6,576 Shares of Alnylam Pharmaceuticals, Inc. $ALNY](https://longbridge.com/en/news/298418429.md)
- [Apimeds Pharmaceuticals adds Co-CEO Sungjoon Chae to board](https://longbridge.com/en/news/298737366.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**